9th Annual Pharma Pricing, Reimbursement & Market Access 2025

9th Annual Pharma Pricing, Reimbursement & Market Access 2025 is organized by Virtue Insight and will be held from Oct 07 - 09, 2025 at Embassy Suites by Hilton Philadelphia Airport, Philadelphia, Pennsylvania, United States of America.

Description:
This Pharma Pricing, Reimbursement & Market Access Conference brings together global stakeholders - including industry leaders, payers, HTA bodies, regulators, physicians, and patient advocates—to explore the latest challenges, opportunities, and innovations shaping access to medicines.

Key Topics & Discussions:

• Value-Based Access Models
• IRA and State-level Pricing Initiatives
• Real-World Evidence (RWE) & Data-Driven Decisions
• HTA Evolution & Global Alignment
• Regulatory Landscape & Policy Updates
• International Pricing System
• Patient-Centric Market Access
• Digital Health & Technology Impact
• Affordability & Equity in Access
• Pricing Transparency & Sustainability
• Early Access, Accelerated Pathways
• Payer Engagement & Negotiation Strategies
• Cross-Functional Collaboration
• Innovative Contracting & Managed Entry Agreements
• Global vs Local Access Strategy
• Working Together – Stakeholders / Industry / Payers / Physicians /Patients

Key Speakers:

• RODNEY EMERSON, Vice President, Pricing & Contracts, Sandoz
• TOM CROCE, VP Global Patient Advocacy, Jazz Pharmaceuticals
• BOXIONG TANG, Former AVP Head of HEOR & Medical Value Access, Agenus
• GREG APOSTOL, VP & Head of Market Access, Alkermes
• KAELYN BUCK, Senior Director, Government Pricing & Contract Operations, Regeneron Pharmaceuticals
• SHANTHY KRISHNARAJAH, Sr. Director, New Products, Patient, Engagement Research Council & IRA, Johnson & Johnson
• DIEGO CORTINA DE LA FUENTE, Director, Value & Access - Global Value, Evidence Strategy, Biogen
• SANKET SHAH, Director, Global Value & HEOR, Jazz Pharmaceuticals
• CHAKITA WILLIAMS, Market Access, Pricing, Value Demonstration Strategy and Operations Director, Bristol Myers Squibb
• OMAR ALI, Head of Payers, Verpora (Former Government Payer, Nice HTA)
• EDWARD MCADAM, Director, Government Pricing, Contracting Operations and Analytics, Indivior
• DRAKE REITER, Director of Pharmacy Operations, Priority Health
• ROSS MARGULIES, Partner & Attorney, Manatt Health
• ANKA G. EHRHARDT, Director, Cell-Based Assays / Analytical Research & Development, Merck
• HEMANTH KANAKAMEDALA, VP, Decision Science & RWE, Recursion
• RAHUL SHENOLIKAR, Lung Cancer Lead, Oncology Outcomes Research, AstraZeneca
• SWAMINATHAN SUBRAMANIAN, Head, US Global Pricing & Contracting, Regeneron Pharmaceuticals
• JAMIE GROSSMAN, National Account Director, HEOR, Bayer
• JOAQUIN F. MOULD, Global HEOR & Value Strategy Director, CSL Seqirus
• DINAKARAN BALASUBRAMANIAN, Head, Commercial Strategy & Insights, Biologics, Dr. Reddy’s Laboratories
• STEPHEN FRAMIL, Corporate Global Head of Accessibility, Merck
• RAHUL MITTAL, Head Strategy & Innovation – North, America, Dr. Reddy’s Laboratories
• IPEK OZER STILLMAN, Head, Global Health Economics, Payer, Value & Patient Access, Takeda
• MICHAEL CIARAMETARO, Managing Director, Avalere Health
• AMADEO SALVADOR, Senior Data Scientist, Abbvie
• PETER BARSCHDORFF, Vice President, Deallus
• CHERYL ROCHE ALEXANDER, Account Experience Specialist, UCB
• USMAN IQBAL, Chief Medical Officer, Julz Pharma
• HEATHER LEIGH FLANNERY, CEO & Co-Founder, AI MINDSystems Foundation
• KELLIE MURPHY, Senior Director, Head of Commercial, Capricor Therapeutics
• AYESHA AZAM, Associate Principal, Avalere Health